Biohaven (BHVN) garners a “Buy” rating from Citi, with a target price of $28, amid expectations for troriluzole FDA approval. Wall Street analysts proje
Biohaven (BHVN) Shares Surge Following Positive Analyst Coverage
Sep 17, 2025
